Related Experiment Video
Updated: Feb 27, 2026
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Current Management Options in Metastatic Renal Cell Cancer
Sittu Govindasamy Dinakaran Gangadaran1
1Medical Oncology, Govt. Royapettah Hospital, Chennai, India.
Abstract:
Renal cancer accounts for 2.4% of all cancers. Localised disease accounts for the majority of renal cancers (70-75%), however 20-25% of these ultimately develop distant metastasis. The median overall survival of un treated metastatic disease is 5 months with 1-year survival of only 29%. The management of metastatic renal cell cancers traditionally relied on systemic immunotherapy with attendant high morbidity but after the year 2005 the use of effective targeted therapy with tolerable side effect profile has improved the survival from 10.2 months in the cytokine era to 17.7 months. This article reviews the past, present and future options in the management of metastatic renal cancer.
Insights
Metastatic renal cell cancer survival has improved significantly since 2005 due to targeted therapies replacing older immunotherapies. This review explores past, present, and future metastatic renal cancer management strategies.
Area of Science:
- Oncology
- Medical Research
Background:
- Renal cell cancer (RCC) represents 2.4% of all cancer diagnoses.
- While localized RCC is common (70-75%), 20-25% metastasize, with a median survival of 5 months.
- Untreated metastatic RCC has a poor prognosis, with only 29% 1-year survival.
Purpose of the Study:
- To review the evolution of metastatic renal cell cancer management.
- To compare traditional immunotherapy with modern targeted therapy.
- To discuss future directions in treating advanced renal cancer.
Main Methods:
- Literature review of studies on renal cell cancer treatment.
- Analysis of survival data from different treatment eras (cytokine vs. targeted therapy).
- Discussion of current and emerging therapeutic options.
Main Results:
- Targeted therapies, introduced after 2005, have improved median survival from 10.2 to 17.7 months.
- Targeted therapies offer a better side effect profile compared to traditional systemic immunotherapy.
- Significant advancements in managing metastatic renal cancer have been achieved.
Conclusions:
- The shift to targeted therapy has markedly improved outcomes for metastatic renal cell cancer patients.
- Continued research into novel therapies is crucial for further improving survival and quality of life.
- A comprehensive understanding of historical and current treatments informs future therapeutic strategies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
01:28Chronic Kidney Disease III: Interprofessional Care
01:30Urinary Tract Calculi III: Medical Management
02:56Treatment Resistant Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...